$IPHA

Innate Pharma SA

Innate Pharma is a clinical-stage biotechnology company developing immunotherapies for cancer patients. Its research uses antibody engineering and target identification to develop antibody-based cancer treatments. Its portfolio includes lacutamab, a wholly owned antibody candidate for certain T cell lymphomas; IPH4502, an antibody-drug conjugate targeting Nectin-4 that is in Phase 1 development for advanced solid tumors; and monalizumab, an immune checkpoint inhibitor partnered with AstraZeneca. Innate also works with biopharmaceutical companies, including Sanofi and AstraZeneca, and academic and research institutions to advance immuno-oncology programs. Innate makes money through collaboration and license agreements, which can provide upfront and milestone payments and equity investments. Its headquarters are in Marseille, France. The company has research and development facilities in France and the United States.

1
1
2

No SEC Form 4 filings for $IPHA in the last 30 days.

See all $IPHA insider activity →
Med

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist

Summit Therapeutics (SMMT) was rejected by the FDA for its lung cancer treatment. Savara (SVRA) awaits a decision on Molgramostim. Eisai and Roche (RHHBY) will present Alzheimer's data, while Acadia (ACAD) will share results for Remlifanserin. Eli Lilly (LLY) and Corbus (CRBP) will discuss weight-loss treatments. Alpha Tau (DRTS) and Innate Pharma (IPHA) will present early cancer data. Sellas (SLS) expects Phase 3 results for Galinpepimut-S.

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

IPHA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning IPHA (Innate Pharma SA). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.

Recent IPHA coverage spans financial news, earnings and regulation.

What's driving IPHA

AlphAI scores every news story that mentions IPHA with an AI model for sentiment and relevance, and aggregates insider trades from Innate Pharma SA's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IPHA

Score

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist

Summit Therapeutics (SMMT) was rejected by the FDA for its lung cancer treatment. Savara (SVRA) awaits a decision on Molgramostim. Eisai and Roche (RHHBY) will present Alzheimer's data, while Acadia (ACAD) will share results for Remlifanserin. Eli Lilly (LLY) and Corbus (CRBP) will discuss weight-loss treatments. Alpha Tau (DRTS) and Innate Pharma (IPHA) will present early cancer data. Sellas (SLS) expects Phase 3 results for Galinpepimut-S.

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

Innate Pharma Q3 Earnings Call Highlights

Innate Pharma (IPHA) completed enrollment in a dose-escalation study with 76 patients across 10+ tumor types, showing preliminary antitumor activity and a favorable safety profile. The company expects to share more data soon. PACIFIC-9 study events are occurring slowly, and CFO Frédéric Lombard will depart by year-end. Innate has received $450M from its AstraZeneca partnership, with up to $825M in potential milestones.

Innate Pharma Q2 Earnings Call Highlights

Innate Pharma reported Q2 earnings, highlighting a €75 million upfront payment, potential milestones up to €465 million, and tiered royalties. The company expects lacutamab may be included in NCCN guidelines and priced between €500,000 and €625,000 per patient. IPH4502 showed preliminary antitumor activity in advanced solid tumors. Innate plans to present phase I data in November. The company has €21.4 million in cash, excluding a €65 million upfront payment and €28 million from an equity offeri

Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate Pharma reported its first half 2026 results, highlighting a strategic partnership with Sobi for lacutamab, a $75M upfront payment, and a €30M equity financing. Key milestones include the initiation of the TELLOMAK-3 Phase 3 trial for lacutamab, expected to report data in Q1 2027, and the presentation of IPH4502 Phase 1 data at ENA 2026. The company also anticipates a PACIFIC-9 Phase 3 readout for monalizumab by year-end. As of June 30, 2026, Innate Pharma had a cash position of €21.4M and

$IPHAMedAI 8/10

Sobi and Innate announce partnership is now effective following completion of closing conditions

Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma (IPH, IPHA) announced their strategic partnership is now effective. Sobi will pay Innate $75 million upfront, with potential milestone payments up to $465 million. Innate will conduct a Phase 3 trial for lacutamab, a treatment for cutaneous T-cell lymphoma, with Sobi receiving exclusive commercialization rights.

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma (NASDAQ:IPHA) completed enrollment in the dose-escalation portion of its Phase I trial of IPH4502, enrolling 76 patients by July 21. The company expects 10 to 15 patients at go-forward doses across post-PADCEV urothelial cancer, head and neck cancer, and NSCLC, with dose-escalation data later in 2024. Innate also awaits primary-endpoint data from AstraZeneca’s PACIFIC-9 monalizumab study by year-end, after a €30M financing extending its cash runway into 2028.

Related tickers